Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on January 15, 2021, and January 18, 2021, with the report filed on January 20, 2021. The registrant, formerly known as Miragen Therapeutics, Inc., officially changed its name to Viridian Therapeutics, Inc. effective January 20, 2021. The company's common stock ticker symbol changed from "MGEN" to "VRDN" on the Nasdaq Stock Market, with a new CUSIP number of 92790C104.
Key Financial Metrics and Compensation
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The financial data provided relates exclusively to executive compensation and severance arrangements:
- Lee Rauch (Outgoing CEO): Entitled to 18 months of base salary, a one-time payment of $541,000, accelerated vesting of all unvested stock options, 18 months of COBRA premiums, and 100% of her 2020 target bonus ($270,500). She will receive a consulting fee of $45,000 per month for an initial three-month term and was granted an option to purchase 15,000 shares at $23.03 per share.
- Jonathan Violin (Incoming CEO): Entitled to an annual base salary of $567,000 and an annual target bonus of 60% of base salary. He was granted an option to purchase 800,075 shares at $23.03 per share, vesting over four years.
Material Changes Versus Prior Period
The filing details significant corporate governance and structural changes rather than operational performance shifts:
- Leadership Transition: Lee Rauch resigned as CEO and Board member effective January 15, 2021. Jonathan Violin, Ph.D., M.B.A., was appointed CEO, Principal Executive Officer, and a member of the Board on the same date.
- New Executive Appointment: Barrett Katz, MD, M.B.A., was appointed Chief Medical Officer effective January 18, 2021.
- Corporate Identity: The company legally changed its name from Miragen Therapeutics, Inc. to Viridian Therapeutics, Inc. and updated its ticker symbol and CUSIP number.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or specific risk factors. Management commentary is limited to the rationale for the leadership changes and the terms of the new employment and separation agreements. The resignation of the former CEO was explicitly stated as not being the result of any disagreements regarding the company's operations, policies, or practices.
Important Facts for Investor Verification
- Verify the new ticker symbol "VRDN" and CUSIP "92790C104" for trading purposes.
- Review the total cost of the separation agreement with Lee Rauch, including the $541,000 lump sum, 18 months of salary, and accelerated equity vesting.
- Confirm the vesting schedule and exercise price ($23.03) for the 800,075 stock options granted to the new CEO, Jonathan Violin.
- Monitor the transition period as the former CEO serves as a consultant for three months at $45,000 per month.